The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort

INTRODUCTION: Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios-Romenets, Silvia, Giraldo, Margarita, Acosta, Natalia, Tobon, Carlos, Ramos, Claudia, Espinosa, Alejandro, Cho, William, Ward, Michael, Clayton, David, Friesenhahn, Michael, Mackey, Howard, Honigberg, Lee, Sanabria Bohorquez, Sandra, Chen, Kewei, Walsh, Trisha, Langlois, Carolyn, Reiman, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021543/
https://www.ncbi.nlm.nih.gov/pubmed/29955659
http://dx.doi.org/10.1016/j.trci.2018.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021543/
https://www.ncbi.nlm.nih.gov/pubmed/29955659
http://dx.doi.org/10.1016/j.trci.2018.02.002

Ejemplares similares